Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts

REFERENCES

• Huang ME, Ye YC, Chen SR, Chai Jr, Lu JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72(2):567 — 572.
   Google Scholar
• Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All-trans-retinoic acid as a differentiating therapy for acute promyelocytic leukemia. Clinical results. Blood 1990;76(9):1704 —1709.
   Google Scholar
• Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri ML, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jacubowski A, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New England Journal of Medicine 1991;324(20): 1385–1393.
   Google Scholar
• Tallman MS, Andersen JW, Appelbaum ASC, Appelbaum FR. All-trans-retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine 1997;337(15):1021 — 1028.
   Google Scholar
• Chen Z, Tong JH, Dong S, Zhu J, Wang ZY, Chen SJ. Retinoic acid regulatory pathways, chromosomal transloca-tions and acute promyelocytic leukemia. Genes Chromosomes and Cancer 1996;15(3):147 — 156.
   Google Scholar
• Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, et al. Expression of Bc1-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999;13 (11 ) : 1881 — 1892.
   Google Scholar
• Athanasiadis I, Kies MS, Miller M, Ganzenko N, Joob A, Marymont M, Rademaker A, Gradishar WJ. Phase II study of all-trans-retinoic acid and alfa-interferon in patients with advanced non-small cell lung cancer. Clinical Cancer Research 1995;1 (9):973 — 979.
   Google Scholar
• Bailey J, Pluda JM, Foli A, Saville MW, Bauza S, Adamson PC, Murphy RF, Cohen RB, Broder S, Yarchoan R. Phase I/ II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a in patients with epidemic Kaposi's sarcoma. Journal of Clinical Oncology 1995;13(8):1966— 1974.
   Google Scholar
• Krupitza G, Hulla W, Dittrich E, Kallay E, Harant H, Huber H, Grunt T, Dittrich C. Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. International Journal of Cancer 1995;61 (5):649— 657.
   Google Scholar
• Massad LS, Turyk M, Bitterman EP, Wilbanks GD. Interferon-alfa and all-trans-retinoic acid reversibly inhibit the in vitro proliferation of cell lines derived from cervical cancers. Gynecologic Oncology 1996;60(3):428— 434.
   Google Scholar
• Moasser MM, Motzer RJ, Khoo KS, Lyn P, Murphy BA, Bosl GJ, Dmitrovsky E. All-trans-retinoic acid for treating germ cell tumors: in vitro activity and results of a phase II trial. Cancer 1995;76 (4): 680 — 686.
   Google Scholar
• Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C, Montaldo PG. Differential effects of N-(4-hydroxyphenypretinamide and retinoic acid on neuro-blastoma cells: apoptosis versus differentiation. Cancer Research 1995;55(4):853–861.
   Google Scholar
• Mangiarotti R, Danova M, Alberici R, Pellicciari C. All-trans retinoic acid (ATRA) induced apoptosis is preceded by G1 arrest in human MCF-7 breast cancer cells. British Journal of Cancer 1998;77(2):186— 191.
   Google Scholar
• Lehmann S, Bengtzen S, Broberg U, Paul C. Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML. Leukemia Research 2000;24(1):19–25.
   Google Scholar
• Lishner M, Curtis JE, Minkin S, McCulloch EA. Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia. Leukemia 1989;3(11):784 —788.
   Google Scholar
• Yang GS, Minden MD, McCulloch EA. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. Leukemia 1994; 8 (12) :2065 — 2075.
   Google Scholar
• Zheng A, Savolainen ER, Koistinen P. All-trans retinoic acid induces apoptosis in acute myeloblastic leukaemia cells. Apoptosis 1997;2(3):319 — 329.
   Google Scholar
• Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89(9):3354 — 3360.
   Google Scholar
• Wang Zhen-Hi. Arsenic compound as anticancer agents. Cancer Chemotherapy and Pharmacology 2001;48(Suppl 1):72–76.
   Google Scholar
• Chen Z, Chen GQ, Shen ZY, Chen SY, Wang ZY. Treatments of acute promyelocytic leukemia with arsenic trioxide compound: in vitro and in vivo. Seminars in Hematology 2001;38(1):26–36.
   Google Scholar
• Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular moni-toring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94(10):3315 — 3324.
   Google Scholar
• Davison K, Mann KIK, Miller WH Jr. Arsenic trioxide: mechanism of action. Seminars in Hematology 2002;39 (2 Suppl 1): 3–7.
   Google Scholar
• Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY. In vitro studies on cellular and molecular mechanism of Arsenic Trioxide (As203) in the treatment of acute promyelocytic leukemia: As203 induces NB4 cell apoptosis with down-regulation of Bc1-2 of PML-RAR(/PML proteins. Blood 1996;88(3):1052— 1061.
   Google Scholar
• Chen GQ, Shi XG, Tang W, Xiong XM, Zhu J, Cai X. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): I. As203 exerts dose-depen-dent dual effects on APL cells. Blood 1997;89(9):3345 — 3353.
   Google Scholar
• Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New England Journal of Medicine 1998;339(19):1341 — 1348.
   Google Scholar
• Akao Y, Mizoguchi H, Kojima S, Naoe T, Ochichi N, Yagi N. Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activations of caspases and downregulation of bc1-2 protein. British Journal of Hematology 1998;102(4):1055 — 1060.
   Google Scholar
• Konig A, Wrazel L, Warrel RP Jr, Rivi R, Pandolfi PP, Jakubowski A, Gabrilove JL. Comparative activity of mel-arsoprol and arsenic trioxide in chronic B-cell leukemia cell lines. Blood 1997;90(2):562 — 570.
   Google Scholar
• Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinical achievable concentrations. Journal of National Cancer Institute 1999;91(9):772 — 778.
   Google Scholar
• Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC, Fermand JP. Arsenic trioxide and melarso-prol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Research 1999;59(5):1041 — 1048.
   Google Scholar
• Puccetti E, Guller S, Orleth A, Bruggenolte N, Hoelzer D, Ottmann OG, Ruthardt M. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Research 2000;60(13):3409 — 3413.
   Google Scholar
• Lehmann S, Bengtzen S, Paul A, Christensson B, Paul C. Effect of arsenic trioxide (As203) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance. European Journal of Haematology 2001;66(6):357 — 364.
   Google Scholar
• Huang XJ, Wiernik PH, Klein RS, Gallagher RE. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Medical Oncology 1999;16(1):58 — 64.
   Google Scholar
• Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, LanotteM, Chen Z, de The H. Combined arsenic trioxide and retinoic acid treatment enhances differentiation and apopto-sis in arsenic resistant NB4 cells. Blood 1998;91(11):4300 — 4310.
   Google Scholar
• Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY. Immu-noenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). Journal of Histochemistry and Cytochemistry 1984;32(2):219 — 229.
   Google Scholar
• Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubici-n + all-trans retinoic acid + granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999;93 (8):2478 — 2484.
   Google Scholar
• Venditti A, Tamburini A, Buccisano F, Scimo MT, Del Poeta G, Maurillo L, Cox MC, Abruzzese E, Tribalto M, Masi M, Amadori S. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes. Annals of Hematology 2000;79 (3):138 — 142.
   Google Scholar
• Sacchi S, Kantarjian HM, Freireich EJ, O'Brien S, Cortes J, Rios MB, Kornblau S, Giles FJ, Koller C, Gajewski J, Talpaz M. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia. Leukemia and Lymphoma 1999;35(5 — 6):483 —489
   Google Scholar
• Bensi L, Longo R, Vecchi A, Messora C, Garagnani L, Bernardi S, Tamassia MG, Sacchi S. Bc1-2 oncoprotein expression in acute myeloid leukemia. Haematologica 1995;80(2):98— 102.
   Google Scholar
• Delia D, Aiello A, Soligo D, Fontanella E, Melani C, Pezzella F, Pierotti MA, Della Porta G. bc1-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992;79(5):1291 — 1298.
   Google Scholar
• Davison K, Mann KK, Waxman S. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute pro-myelocytic leukemia cells. Blood 2004;103(9):3496— 3502.
   Google Scholar
• Cai X, Yu Y, Huang Y, Zhang L, Jia PM. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia 2003;17:1333 —1337.
   Google Scholar
• Park JW, Choi YJ, jang MA, Baek SH, Lim JH, Passaniti T, Know TK. Arsenic trioxide induces G2/M growth arrest and apoptosis after Caspase-3 activation and bc1-2 phospolylation in promonocytic U937 cells. Biochemical and Byophysical Research Communications 2001;286: 726–738.
   Google Scholar
• Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomi-enne C, Groenemeyer H. Retionic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nature Medicine 2001;7(6):680— 686.
   Google Scholar
• Lotan R. Effect of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochimica Biophysica Acta 1980;605(1):33–91.
   Google Scholar
• Rojewski MT, Baldus C, Knauf W, Thiel E, Shrezenmeier H. Dual effects of arsenic trioxide (As203) on non-acute promyelocytic leukemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. British Journal of Haematology 2002;116 (3): 555 — 563.
   Google Scholar
• Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, et al. All-trans retinoic acid/ As203 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101(15):5328 — 5335.
   Google Scholar